

Christian Manzardo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1865664/publications.pdf>

Version: 2024-02-01

68
papers

1,578
citations

346980

22
h-index

371746

37
g-index

70
all docs

70
docs citations

70
times ranked

2990
citing authors

#	ARTICLE	IF	CITATIONS
1	Preserved central nervous system functioning after use of romidepsin as a latency-reversing agent in an HIV cure strategy. <i>Aids</i> , 2022, 36, 363-372.	1.0	3
2	Gut microbiome signatures linked to HIV-1 reservoir size and viremia control. <i>Microbiome</i> , 2022, 10, 59.	4.9	19
3	Healthcare delivery for HIV-positive people with tuberculosis in Europe. <i>HIV Medicine</i> , 2021, 22, 283-293.	1.0	6
4	Network meta-analysis of post-exposure prophylaxis randomized clinical trials. <i>HIV Medicine</i> , 2021, 22, 218-224.	1.0	2
5	Pharmacokinetic/pharmacodynamic analysis of romidepsin used as an HIV latency reversing agent. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 1032-1040.	1.3	2
6	Post-exposure prophylaxis for HIV infection in sexual assault victims. <i>HIV Medicine</i> , 2020, 21, 43-52.	1.0	12
7	Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection. <i>Aids</i> , 2020, 34, 2269-2274.	1.0	8
8	In vivo Effects of Romidepsin on T-Cell Activation, Apoptosis and Function in the BCN02 HIV-1 Kick&Kill Clinical Trial. <i>Frontiers in Immunology</i> , 2020, 11, 418.	2.2	23
9	HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). <i>Frontiers in Immunology</i> , 2020, 11, 823.	2.2	55
10	HTLV testing of solid organ transplant donors. <i>Clinical Transplantation</i> , 2019, 33, e13670.	0.8	8
11	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). <i>EClinicalMedicine</i> , 2019, 11, 65-80.	3.2	52
12	Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study. <i>International Journal of Infectious Diseases</i> , 2019, 88, 73-79.	1.5	5
13	Epidemiological changes of acute/recent human immunodeficiency virus type 1 infection in Barcelona, Spain (1997-2015): a prospective cohort study. <i>Clinical Microbiology and Infection</i> , 2019, 25, 878-884.	2.8	7
14	Discontinuation of dolutegravir, elvitegravir/cobicistat and raltegravir because of toxicity in a prospective cohort. <i>HIV Medicine</i> , 2019, 20, 237-247.	1.0	32
15	Sfilis maligna, una presentaci3n de sfilis a tener en cuenta. <i>Actas Dermo-sifilogrÃficas</i> , 2019, 110, 232-237.	0.2	9
16	Sexual acquisition of <sc>HIV</sc> infection after solid organ transplantation: Late presentation and potentially fatal complications. <i>Transplant Infectious Disease</i> , 2018, 20, e12894.	0.7	5
17	Community-Acquired Legionella Pneumonia in Human Immunodeficiency Virus-Infected Adult Patients: A Matched Case-Control Study. <i>Clinical Infectious Diseases</i> , 2018, 67, 958-961.	2.9	9
18	Prevalence and risk factors of mild chronic renal failure in HIV-infected patients: influence of female gender and antiretroviral therapy. <i>Brazilian Journal of Infectious Diseases</i> , 2018, 22, 193-201.	0.3	13

#	ARTICLE	IF	CITATIONS
19	Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study. <i>American Journal of Transplantation</i> , 2018, 18, 2513-2522.	2.6	32
20	Human immunodeficiency virus-infected liver transplant recipients with incidental hepatocellular carcinoma: A prospective multicenter nationwide cohort study. <i>Liver Transplantation</i> , 2017, 23, 645-651.	1.3	3
21	Regional differences in the management and outcome of kidney transplantation in patients with human immunodeficiency virus infection: A 3-year retrospective cohort study. <i>Transplant Infectious Disease</i> , 2017, 19, e12724.	0.7	3
22	Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis. <i>BMC Nephrology</i> , 2017, 18, 58.	0.8	17
23	Community-Acquired Pneumococcal Pneumonia in Virologically Suppressed HIV-Infected Adult Patients. <i>Chest</i> , 2017, 152, 295-303.	0.4	15
24	Neurological involvement in patients with acute/recent HIV-1 infection. A case-control study. <i>Journal of NeuroVirology</i> , 2017, 23, 679-685.	1.0	4
25	Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 205-209.	1.3	28
26	Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2857-2861.	1.3	12
27	Liver Retransplantation in Patients With HIV-1 Infection: An International Multicenter Cohort Study. <i>American Journal of Transplantation</i> , 2016, 16, 679-687.	2.6	11
28	An Update on Heart Transplantation in Human Immunodeficiency Virus-Infected Patients. <i>American Journal of Transplantation</i> , 2016, 16, 21-28.	2.6	36
29	Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV-positive persons. <i>HIV Medicine</i> , 2016, 17, 83-88.	1.0	81
30	Cyclosporine A in addition to standard ART during primary HIV-1 infection: pilot randomized clinical trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 72, dkw462.	1.3	9
31	Safe Reduction in CD4 Cell Count Monitoring in Stable, Virologically Suppressed Patients With HIV Infection or HIV/Hepatitis C Virus Coinfection. <i>Clinical Infectious Diseases</i> , 2016, 62, 1578-1585.	2.9	5
32	IFN-free therapy for HIV/HCV-coinfected patients within the liver transplant setting. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3195-3201.	1.3	11
33	Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma. <i>Hepatology</i> , 2016, 63, 488-498.	3.6	27
34	Corrigendum to "Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study" [Hepatology 2015;62:92-100]. <i>Journal of Hepatology</i> , 2016, 64, 757.	1.8	0
35	Voriconazole and cobicistat-boosted antiretroviral salvage regimen co-administration to treat invasive aspergillosis in an HIV-infected patient. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1125-1127.	1.3	7
36	A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1982-1986.	1.3	9

#	ARTICLE	IF	CITATIONS
37	A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 1987-1993.	1.3	16
38	Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection. <i>Journal of Virology</i> , 2016, 90, 5231-5245.	1.5	31
39	Pregnancy in a renal transplant recipient with HIV-1 infection: a case report. <i>Antiviral Therapy</i> , 2015, 20, 267-271.	0.6	0
40	Epidemiology of infections by HIV, Syphilis, Gonorrhoea and Lymphogranuloma Venereum in Barcelona City: a population-based incidence study. <i>BMC Public Health</i> , 2015, 15, 1015.	1.2	37
41	Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease. <i>Aids</i> , 2015, 29, 1493-1504.	1.0	9
42	Trends in Transmission of Drug Resistance and Prevalence of Non-B Subtypes in Patients with Acute or Recent HIV-1 Infection in Barcelona in the Last 16 Years (1997-2012). <i>PLoS ONE</i> , 2015, 10, e0125837.	1.1	23
43	Infection with human retroviruses other than HIV-1: HIV-2, HTLV-1, HTLV-2, HTLV-3 and HTLV-4. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 947-963.	2.0	24
44	Opportunistic infections and immune reconstitution inflammatory syndrome in HIV-1-infected adults in the combined antiretroviral therapy era: a comprehensive review. <i>Expert Review of Anti-Infective Therapy</i> , 2015, 13, 751-767.	2.0	48
45	Evaluation of an antibody avidity index method for detecting recent human immunodeficiency virus type 1 infection using an automated chemiluminescence immunoassay. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015, 33, 238-242.	0.3	2
46	Clinical progression of severely immunosuppressed HIV-infected patients depends on virological and immunological improvement irrespective of baseline status. <i>Journal of Antimicrobial Chemotherapy</i> , 2015, 70, dkv272.	1.3	2
47	Pegylated interferon plus ribavirin in HIV-infected patients with recurrent hepatitis C after liver transplantation: A prospective cohort study. <i>Journal of Hepatology</i> , 2015, 62, 92-100.	1.8	20
48	Structured Treatment Interruptions and Low Doses of IL-2 in Patients with Primary HIV Infection. Inflammatory, Virological and Immunological Outcomes. <i>PLoS ONE</i> , 2015, 10, e0131651.	1.1	5
49	HIV treatment outcomes in Europe and North America: what can we learn from the differences?. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 523-526.	2.0	12
50	Update on antiretroviral treatment during primary HIV infection. <i>Expert Review of Anti-Infective Therapy</i> , 2014, 12, 793-807.	2.0	23
51	Impact of Risk Factors for Specific Causes of Death in the First and Subsequent Years of Antiretroviral Therapy Among HIV-Infected Patients. <i>Clinical Infectious Diseases</i> , 2014, 59, 287-297.	2.9	136
52	Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. <i>Aids</i> , 2014, 28, 325-334.	1.0	62
53	Effect of Maraviroc Intensification on HIV-1-Specific T Cell Immunity in Recently HIV-1-Infected Individuals. <i>PLoS ONE</i> , 2014, 9, e87334.	1.1	15
54	Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate): a new paradigm for HIV-1 treatment. <i>AIDS Reviews</i> , 2014, 16, 35-42.	0.5	16

#	ARTICLE	IF	CITATIONS
55	Community-associated methicillin-resistant <i>Staphylococcus aureus</i> infections in HIV-infected patients in Spain. <i>Journal of Infection</i> , 2013, 66, 199-201.	1.7	5
56	Optimal timing for initiation of highly active antiretroviral therapy in treatment-naïve human immunodeficiency virus-1-infected individuals presenting with AIDS-defining diseases: the experience of the PISCIS Cohort. <i>Clinical Microbiology and Infection</i> , 2013, 19, 646-653.	2.8	19
57	Durability of first ART regimen and risk factors for modification, interruption or death in HIV-positive patients starting ART in Europe and North America 2002–2009. <i>Aids</i> , 2013, 27, 803-813.	1.0	70
58	Renal Dysfunction in the Setting of HIV/AIDS. <i>Current HIV/AIDS Reports</i> , 2012, 9, 187-199.	1.1	22
59	Liver Retransplantation in HIV-Infected Patients: A Prospective Cohort Study. <i>American Journal of Transplantation</i> , 2012, 12, 2465-2476.	2.6	7
60	Renal transplantation in HIV-infected patients: 2010 update. <i>Kidney International</i> , 2011, 79, 825-842.	2.6	65
61	Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis. <i>PLoS ONE</i> , 2011, 6, e26009.	1.1	16
62	Immune Reconstitution in Severely Immunosuppressed Antiretroviral-Naive HIV Type 1-Infected Patients Using a Nonnucleoside Reverse Transcriptase Inhibitor-Based or a Boosted Protease Inhibitor-Based Antiretroviral Regimen: Three-Year Results (The Advanz Trial): A Randomized, Controlled Trial. <i>AIDS Research and Human Retroviruses</i> , 2010, 26, 747-757.	0.5	16
63	Simultaneous Pancreas-Kidney Transplantation in HIV-infected Patients: A Case Report and Literature Review. <i>Transplantation Proceedings</i> , 2010, 42, 3887-3891.	0.3	31
64	Communicable diseases in the immigrant population attended to in a tropical medicine unit: Epidemiological aspects and public health issues. <i>Travel Medicine and Infectious Disease</i> , 2008, 6, 4-11.	1.5	73
65	Patients presenting with AIDS in the HAART era: a collaborative cohort analysis. <i>Aids</i> , 2008, 22, 2461-2469.	1.0	51
66	Optimal Timing and Best Antiretroviral Regimen in Treatment-naive HIV-Infected Individuals with Advanced Disease. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2007, 46, S9-S18.	0.9	35
67	Cidofovir for cytomegalovirus reactivation in pediatric patients after hematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2005, 34, 129-132.	1.6	52
68	Central nervous system opportunistic infections in developed countries in the highly active antiretroviral therapy era. <i>Journal of NeuroVirology</i> , 2005, 11, 72-82.	1.0	44